Copyright Reports & Markets. All rights reserved.

Global Cancer Biologics Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Cancer Biologics Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Monoclonal Antibodies
      • 1.4.3 Vaccines
      • 1.4.4 Cell and Gene Therapy
      • 1.4.5 Others
    • 1.5 Market by Application
      • 1.5.1 Global Cancer Biologics Market Share by Application (2014-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Cancer Biologics Market Size
    • 2.2 Cancer Biologics Growth Trends by Regions
      • 2.2.1 Cancer Biologics Market Size by Regions (2014-2025)
      • 2.2.2 Cancer Biologics Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Cancer Biologics Market Size by by Players
      • 3.1.1 Global Cancer Biologics Revenue by by Players (2014-2019)
      • 3.1.2 Global Cancer Biologics Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Cancer Biologics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Cancer Biologics Key Players Head office and Area Served
    • 3.3 Key Players Cancer Biologics Product/Solution/Service
    • 3.4 Date of Enter into Cancer Biologics Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Cancer Biologics Market Size by Type (2014-2019)
    • 4.2 Global Cancer Biologics Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Cancer Biologics Market Size (2014-2019)
    • 5.2 Cancer Biologics Key Players in United States
    • 5.3 United States Cancer Biologics Market Size by Type
    • 5.4 United States Cancer Biologics Market Size by Application

    6 Europe

    • 6.1 Europe Cancer Biologics Market Size (2014-2019)
    • 6.2 Cancer Biologics Key Players in Europe
    • 6.3 Europe Cancer Biologics Market Size by Type
    • 6.4 Europe Cancer Biologics Market Size by Application

    7 China

    • 7.1 China Cancer Biologics Market Size (2014-2019)
    • 7.2 Cancer Biologics Key Players in China
    • 7.3 China Cancer Biologics Market Size by Type
    • 7.4 China Cancer Biologics Market Size by Application

    8 Japan

    • 8.1 Japan Cancer Biologics Market Size (2014-2019)
    • 8.2 Cancer Biologics Key Players in Japan
    • 8.3 Japan Cancer Biologics Market Size by Type
    • 8.4 Japan Cancer Biologics Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Cancer Biologics Market Size (2014-2019)
    • 9.2 Cancer Biologics Key Players in Southeast Asia
    • 9.3 Southeast Asia Cancer Biologics Market Size by Type
    • 9.4 Southeast Asia Cancer Biologics Market Size by Application

    10 India

    • 10.1 India Cancer Biologics Market Size (2014-2019)
    • 10.2 Cancer Biologics Key Players in India
    • 10.3 India Cancer Biologics Market Size by Type
    • 10.4 India Cancer Biologics Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Cancer Biologics Market Size (2014-2019)
    • 11.2 Cancer Biologics Key Players in Central & South America
    • 11.3 Central & South America Cancer Biologics Market Size by Type
    • 11.4 Central & South America Cancer Biologics Market Size by Application

    12 International Players Profiles

    • 12.1 Roche
      • 12.1.1 Roche Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Cancer Biologics Introduction
      • 12.1.4 Roche Revenue in Cancer Biologics Business (2014-2019)
      • 12.1.5 Roche Recent Development
    • 12.2 Novartis
      • 12.2.1 Novartis Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Cancer Biologics Introduction
      • 12.2.4 Novartis Revenue in Cancer Biologics Business (2014-2019)
      • 12.2.5 Novartis Recent Development
    • 12.3 Eli Lilly
      • 12.3.1 Eli Lilly Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Cancer Biologics Introduction
      • 12.3.4 Eli Lilly Revenue in Cancer Biologics Business (2014-2019)
      • 12.3.5 Eli Lilly Recent Development
    • 12.4 Sanofi
      • 12.4.1 Sanofi Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Cancer Biologics Introduction
      • 12.4.4 Sanofi Revenue in Cancer Biologics Business (2014-2019)
      • 12.4.5 Sanofi Recent Development
    • 12.5 Celgene
      • 12.5.1 Celgene Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Cancer Biologics Introduction
      • 12.5.4 Celgene Revenue in Cancer Biologics Business (2014-2019)
      • 12.5.5 Celgene Recent Development
    • 12.6 Pfizer
      • 12.6.1 Pfizer Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Cancer Biologics Introduction
      • 12.6.4 Pfizer Revenue in Cancer Biologics Business (2014-2019)
      • 12.6.5 Pfizer Recent Development
    • 12.7 Bayer
      • 12.7.1 Bayer Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Cancer Biologics Introduction
      • 12.7.4 Bayer Revenue in Cancer Biologics Business (2014-2019)
      • 12.7.5 Bayer Recent Development
    • 12.8 Johnson & Johnson
      • 12.8.1 Johnson & Johnson Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Cancer Biologics Introduction
      • 12.8.4 Johnson & Johnson Revenue in Cancer Biologics Business (2014-2019)
      • 12.8.5 Johnson & Johnson Recent Development
    • 12.9 Bristol-Myers Squibb
      • 12.9.1 Bristol-Myers Squibb Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Cancer Biologics Introduction
      • 12.9.4 Bristol-Myers Squibb Revenue in Cancer Biologics Business (2014-2019)
      • 12.9.5 Bristol-Myers Squibb Recent Development
    • 12.10 Merck
      • 12.10.1 Merck Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Cancer Biologics Introduction
      • 12.10.4 Merck Revenue in Cancer Biologics Business (2014-2019)
      • 12.10.5 Merck Recent Development
    • 12.11 Amgen

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Cancer Biologic is a medicinal preparation created by a biological process, it is used to treatment and remission cancer symptoms.
      In 2018, the global Cancer Biologics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Cancer Biologics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cancer Biologics development in United States, Europe and China.

      The key players covered in this study
      Roche
      Novartis
      Eli Lilly
      Sanofi
      Celgene
      Pfizer
      Bayer
      Johnson & Johnson
      Bristol-Myers Squibb
      Merck
      Amgen

      Market segment by Type, the product can be split into
      Monoclonal Antibodies
      Vaccines
      Cell and Gene Therapy
      Others

      Market segment by Application, split into
      Hospitals
      Clinics
      Others

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Cancer Biologics status, future forecast, growth opportunity, key market and key players.
      To present the Cancer Biologics development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Cancer Biologics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now